Placebo to QVM149
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
AsthmaRespiratory
Phase 3
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
RecruitingNCT05776927
Start: 2026-08-04End: 2029-01-30Target: 188Updated: 2026-09-11
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
Not yet recruitingCTIS2022-502365-26-00
Target: 22Updated: 2026-06-02
A study to evaluate the efficacy and safety of QVM149 (indacaterol
acetate / glycopyrronium bromide / mometasone furoate) versus salmeterol
xinafoate/fluticasone propionate in children from 12 years to less than 18 years of
age with asthma.
Active, not recruitingPACTR202607586774191
Start: 2026-07-08Target: 32Updated: 2026-08-03